AzTrials
AzTrials

Acute Kidney InjuryAMOSSNCT02338895

Algorithm for Oliguria in Septic Shock

An observational study of Acute Kidney Injury, run by King Faisal Specialist Hospital & Research Center at 1 site in Saudi Arabia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Acute Kidney Injury (AKI) develops in 88% to 30% of critically ill patients admitted to an intensive care unit and is a strong predictor of mortality.Therefore any management strategy that prevents progression of renal risk to injury or failure has the potential to improve outcomes in these patients.Conventional… Read more about this study

Who is it for?
Ages 14 years and older
Conditions the study is for
Acute Kidney Injury
What is being tested?
Ultrasound
Type of treatment
Medical device
How many people
40 participants
Where
1 siteSaudi Arabia
Study dates
Sep 2014to Sep 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Critically ill patients with septic shock presenting with acute oliguria

Who may be able to join

  • Critically ill, adult patients AND with acute oliguric renal failure AND within 6 hours of presentation

Who cannot join

  • i. Patients with pre-existing chronic renal failure ii. Patients on renal replacement therapy/ Dialysis iii. Patients with poor sonographic windows

Trial locations and contacts

1 site in 1 country.

Iqbal Hussain, MD contact

966533215378

hiqbal@kfshrc.edu.sa

Nawal Salahuddin, MD,FCCP contact

966551948786

nsalahuddin@kfshrc.edu.sa

Saudi Arabia1 site, 1 recruiting
  • King Faisal specialist Hospital & Research Center

    Riyadh, Ar Riyadh, 11211

    Iqbal Hussain, MD, 966533215378, hiqbal@kfshrc.edu.sa

    Nawal Salahuddin, MD,FCCP, 966551948786, nsalahuddin@kfshrc.edu.sa

    Recruiting

Other trials in Saudi Arabia

About this study

Official title: An Ultrasound- Guided Algorithm for the Management of Oliguria in Septic Shock

Acute Kidney Injury (AKI) develops in 88% to 30% of critically ill patients admitted to an intensive care unit and is a strong predictor of mortality.Therefore any management strategy that prevents progression of renal risk to injury or failure has the potential to improve outcomes in these patients.Conventional management of acute oliguria in shock has been to blindly 'push' fluids to improve renal perfusion or to give loop diuretics once fluid loading has been considered as accomplished. However both volume overload and 'blind' attempts at fluid removal can worsen renal injury and have been associated with higher mortality by venous overcongestion and inappropriate hypovolemia. It seems reasonable to assume that a bedside test to visualize volume status and renal perfusion may assist in improving outcomes in this cohort.The investigators developed a goal-directed ultrasonographic protocol to provide immediate hemodynamic information in acutely oliguric patients with shock as well as a management algorithm for guiding therapy. The investigators incorporated IVC diameter measurement, respiratory variation and response to a passive leg raise to assess whether further fluid boluses were required and a measurement of renal perfusion to determine whether diuretics or renal replacement therapy were indicated. The investigators aim to measure the effects of this management protocol on the rates of AKI in the study participants as compared to prior to the implementation of the protocol.The study design is a prospective, observational. Since this is a proof of concept study, the projected sample size is 40 patients. An interim analysis will be carried out after 20 patients are enrolled and a further 20 will be enrolled as necessary

Read the detailed description

BACKGROUND \& INTRODUCTION:

Acute Kidney Injury (AKI) develops in 88% to 30% of critically ill patients admitted to an intensive care unit. While AKI of any severity is a strong predictor of mortality (1-4), both morbidity and mortality increase with increasing severity of renal injury(2). Therefore any management strategy that prevents progression of renal risk to injury or failure has the potential to improve outcomes in these patients.

Conventional management of acute oliguria in shock has been to blindly 'push' fluids to improve renal perfusion or to give loop diuretics once fluid loading has been considered as accomplished. However both volume overload and 'blind' attempts at fluid removal can worsen renal injury and have been associated with higher mortality by venous overcongestion (5) and inappropriate hypovolemia (6-8). It seems reasonable to assume that a bedside test to visualize volume status and renal perfusion may assist in improving outcomes in this cohort. Intensive care unit (ICU) bedside ultrasound has become the standard of care for critically ill patients(9-18). In patients with shock, inferior vena cava ultrasonographic evaluation for 'fluid responsiveness' is routinely used to direct resuscitation (19-21) by direct measurement of IVC diameter and respiratory variation or by the response to a noninvasive fluid bolus from a passive leg raise (22). Doppler ultrasound of intrarenal vessels has also been described as a tool to assess renal perfusion (23-27).

The investigators developed a goal-directed ultrasonographic protocol to provide immediate hemodynamic information in acutely oliguric patients with shock as well as a management algorithm for guiding therapy. The investigators incorporated IVC diameter measurement, respiratory variation and response to a passive leg raise to assess whether further fluid boluses were required and a measurement of renal perfusion to determine whether diuretics or renal replacement therapy were indicated.

The objectives are to measure the effects of this management protocol on the rates of AKI in the study participants as compared to prior to the implementation of the protocol.

METHODS:

  1. Study Design: Prospective, Observational 2. Study Patients:
  • Inclusion criteria: Critically ill, adult patients AND with acute oliguric renal failure AND within 6 hours of presentation
  • Exclusion criteria:
  1. Patients with pre-existing chronic renal failure ii. Patients on renal replacement therapy/ Dialysis iii. Patients with poor sonographic windows
  2. Variables to be measured:
  • Dependent variables:
  1. Demographic identifiers; age, gender, comorbidity, admitting diagnosis, APACHE II scores, b. Renal perfusion as measured by color Doppler c. Daily fluid balance, d. Mean hourly urine output, e. Vasopressor use, f. Daily serum Creatinine g. Response to diuretics h. Dose of diuretic that resulted in urine output
  • Outcome variables:
  1. Incidence of renal failure (classified into RIFLE categories; Risk, Injury, Failure, Loss of Function, End-Stage: see Appendix 1),
  2. ICU length of Stay,
  3. ICU mortality

Materials \& Methodologies:

  1. Screening \& Enrollment of patients:
  2. All ICU patients admitted to the ICU will be screened for enrollment.
  3. Those meeting inclusion criteria will have their Demographic information entered in Case Record Forms (Appendix 2: Sample CRF)
  4. Ultrasound examinations will be carried out and results entered into the CRF.
  • For patients found to be intravascularly dehydrated (those with > 2 cm IVC diameter (IVCd) or >15% variation in IVCd or an increase of > 15% in IVCd with a passive leg raise maneuver), the results will be communicated to the managing ICU team for fluid resuscitation
  • For patients found to be adequately hydrated, renal perfusion will be assessed by observing flow in the interlobar and arcuate vessels by colour Doppler and the renal resistive index will be measured.
  • The results of no perfusion or perfusion present will be communicated to the managing ICU team for recommendation of high dose diuresis
  1. Ultrasonographic assessment of Inferior Vena Cava Measurement of the inferior vena cava diameter, and respiratory variation by ultrasound (http://www.criticalecho.com/content/tutorial-4-volume-status-and-preload-responsiveness-assessment) Ultrasonographic assessment of the IVC will be done using a transthoracic, subcostal approach. The transducer will be positioned just below the xiphisternum 1-2cms to the right of the midline, with the marker dot pointing towards the sternal notch. After obtaining a 2-D image of the IVC entering the right atrium and verifying that the IVC visualization is not lost during movements of respiration, an M-mode line will be placed through the IVC 1 cm caudal from its junction with the hepatic vein, and an M-mode tracing obtained. This placement ensures that the intrathoracic IVC is not measured during any part of the respiratory cycle. The M-mode tracing will be recorded through 3- 4 respiratory cycles, the image frozen and using calipers, the maximum and minimum diameters of the IVC tracing measured. IVC variation will be quantified by measuring the difference between the maximum and minimum diameters on the M-mode tracing. Ultrasonographic assessment of Renal Perfusion by color Doppler Vessel localization and a semi-quantitative evaluation of renal perfusion will be carried out using the following staging method. (http://link.springer.com/chapter/10.1007%2F978-3-642-10286-8_31 - page-1) Stage Quality of Renal Perfusion by color Doppler 0 Unidentifiable vessels 1 Few vessels in vicinity of hilum 2 Hilar and intralobar vessels in most of renal parenchyma 3 Renal vessels identifiable until the arcuate arteries in the entire field of view
  2. Statistical Methods:
  3. Sample size \& Sampling: Consecutive admissions to the ICU will be enrolled. Since this is a proof of concept study, the projected sample size is 40 patients. An interim analysis will be carried out after 20 patients are enrolled and a further 20 will be enrolled as necessary
  4. Analysis: Categorical variables will be reported as proportions or percentages, continuous variables as means or medians. Differences between groups will be estimated using CHI2, student t test or Mann-Whitney U test, as appropriate. Rates of renal injury from historical controls will be compared to rates measured using t test for paired samples. A p value =0.05 will be considered significant. SPSS version 22.0 will be used for all analysis.

ETHICAL CONSIDERATIONS:

  1. Informed Consent for ultrasonographic examination. The use of use of ultrasound for the assessment and management of critically ill patients in the ICU and emergency room is considered as standard of care and is routinely practiced in ICUs around the world. Since ultrasound evaluation has become incorporated into usual ICU practice, written consent is not required in its routine use. We therefore ask for a waiver of informed consent since we will not be performing any deviation from usual ICU care and our study is simply a collection of practice into a protocolized form. (Please see References 9-27)
  2. Research Advisory Committee (RAC) Review This protocol will be reviewed and approved by the hospital Research Advisory committee responsible for oversight of the study.
  3. Subject Confidentiality \& Protection of Rights of Control Subjects All case record forms, reports and other records will be identified only by the Study Identification Number (SID) to maintain subject confidentiality. All records will be kept in a password-protected file. All computer entry and networking programs will be done using SIDs only.
  4. Study Modification/Discontinuation The study may be modified or discontinued at any time by the primary investigators and or Research Advisory Committee as part of their duties to ensure that research subjects are protected.
Being tested
Ultrasound
Keywords
acute kidney injury, oliguria,renal ultrasound
Medical subject headings
Acute Kidney Injury, Oliguria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • UltrasoundDevice

    Ultrasound of inferior vena cava and kidneys

Study groups in NCT02338895
Study groupRoleWhat they receive
acutly oliguric patients with ultrasoundPatients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
Receives: Device: Ultrasound

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. acute Kidney Injury

    Measured: 28 days

Secondary outcomes (1)
  1. mortality

    Measured: 28 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jan 2015 (estimated)
  2. Study startSep 2014
  3. Primary completionSep 2015 (estimated)
  4. Study completionSep 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02338895
Sponsor's protocol ID
RAC # 2141039
Acronym
AMOSS
Status last verified
Jan 2015
First submitted
11 Jan 2015
Last updated
26 Jan 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Kidney Injury, run by King Faisal Specialist Hospital & Research Center at 1 site in Saudi Arabia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Iqbal Hussain, MD (966533215378, hiqbal@kfshrc.edu.sa), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

acute Kidney Injury (time frame: 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2015.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in